

Diane Brisson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7122865/publications.pdf>

Version: 2024-02-01

28
papers

757
citations

567281

15
h-index

526287

27
g-index

28
all docs

28
docs citations

28
times ranked

1448
citing authors

#	ARTICLE	IF	CITATIONS
1	Adaptations of placental and cord blood ABCA1 DNA methylation profile to maternal metabolic status. <i>Epigenetics</i> , 2013, 8, 1289-1302.	2.7	86
2	Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis. <i>Human Gene Therapy</i> , 2016, 27, 916-925.	2.7	75
3	Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 313-320.	5.7	72
4	Simplified Canadian Definition for Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1210-1214.	1.7	62
5	Epipolymorphisms within lipoprotein genes contribute independently to plasma lipid levels in familial hypercholesterolemia. <i>Epigenetics</i> , 2014, 9, 718-729.	2.7	57
6	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. <i>Clinical Chemistry</i> , 2018, 64, 355-362.	3.2	47
7	Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1161-1167.e3.	1.5	42
8	Placental DNA Methylation Adaptation to Maternal Glycemic Response in Pregnancy. <i>Diabetes</i> , 2018, 67, 1673-1683.	0.6	42
9	The potential applications of Apolipoprotein E in personalized medicine. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 154.	3.4	40
10	Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia. <i>European Heart Journal</i> , 2017, 38, ehw135.	2.2	38
11	The "hypertriglyceridemic waist" phenotype and glucose intolerance in pregnancy. <i>Cmaj</i> , 2010, 182, E722-E725.	2.0	33
12	Large-scale deletions of the ABCA1 gene in patients with hypoalphalipoproteinemia. <i>Journal of Lipid Research</i> , 2018, 59, 1529-1535.	4.2	22
13	Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 742-747.	1.5	20
14	Low plasma adiponectin exacerbates the risk of premature coronary artery disease in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2008, 196, 262-269.	0.8	18
15	Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 403-414.	2.4	16
16	Dissection of Clinical and Gene Expression Signatures of Familial versus Multifactorial Chylomicronemia. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa056.	0.2	14
17	Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experience. <i>Atherosclerosis</i> , 2020, 310, 54-63.	0.8	12
18	Non-Alcoholic Fatty Liver in Patients with Chylomicronemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 669.	2.4	11

#	ARTICLE	IF	CITATIONS
19	The Lipid Accumulation Product for the Early Prediction of Gestational Insulin Resistance and Glucose Dysregulation. <i>Journal of Women's Health</i> , 2013, 22, 362-367.	3.3	10
20	Influence of Abdominal Obesity on the Lipid-Lipoprotein Profile in Apoprotein E2/4 Carriers: The Effect of an Apparent Duality. <i>Journal of Lipids</i> , 2015, 2015, 1-10.	4.8	10
21	Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 64.	2.4	9
22	Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry. <i>Canadian Journal of Cardiology</i> , 2022, 38, 311-319.	1.7	7
23	Association between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and hypertension. <i>Hypertension Research</i> , 2016, 39, 467-474.	2.7	6
24	Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 403-414.	5.0	3
25	Gene expression profiles of recurrent acute pancreatitis risk in patients with sustained chylomicronemia. <i>Endocrine Journal</i> , 2020, 67, 1157-1161.	1.6	3
26	Association study between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and metabolic syndrome. <i>BMC Medical Genetics</i> , 2018, 19, 130.	2.1	1
27	Association of common gene-smoking interactions with elevated plasma apolipoprotein B concentration. <i>Lipids in Health and Disease</i> , 2020, 19, 98.	3.0	1
28	Palmar Striated Xanthomas in Clinical Practice. <i>Journal of the Endocrine Society</i> , 2022, 6, .	0.2	0